ArticleExperimental and therapeutic medicine2026
Outcomes of transanal total mesorectal excision with ultra-low anterior resection: A single institute propensity-matched cohort study.
Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultra-low anterior resection (ULAR) and total mesorectal excision (TME) are sphincter-preserving treatments for low rectal cancer. However, these techniques face challenges in patients with a narrow pelvis, particularly those with a high BMI. Transanal TME (TaTME) was introduced as a promising treatment approach, but outcomes have varied, leading to some controversy. The present study compared the mid-term oncological and postoperative outcomes, with a median follow-up time of 3.8 years, in patients who underwent TaTME with ULAR (TaTME cohort) or ULAR alone (ULAR cohort). A propensity-matched cohort of 78 patients (TaTME, n=19; ULAR, n=59) was analysed using descriptive statistics, Cox proportional hazard models and Kaplan-Meier survival analyses. Outcomes included progression-free survival (PFS), overall survival and surgical complications. The TaTME group exhibited a longer operative time (554 vs. 322 min; P=0.002) but no conversions to open surgery compared with 4 patients in the ULAR group. No cases of positive circumferential resection margins or anastomotic leakage were observed in the TaTME group. The rate of postoperative sexual dysfunction appeared higher in the TaTME group (3/16 vs. 1/58; P=0.043); however, the absolute number of cases was small and this finding should be interpreted with caution. No other postoperative complications, including anastomotic leak, sepsis or ileus, differed significantly between groups. There was no significant difference in the 3-year PFS rate between the TaTME and ULAR groups (88 vs. 70%; P=0.080) nor in the disease-free survival rate (88 vs. 80%; P=0.259). The TaTME cohort also demonstrated lower risks of recurrence and mortality, although these were not statistically significant. Therefore, TaTME with ULAR appears feasible for patients with low rectal cancer and high BMI, with encouraging surgical outcomes. However, due to the limited sample size and absence of stage IV patients in the TaTME group, more multicentre studies are required to validate long-term efficacy and generalisability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.